MD - MEDNAX, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
Sunrise,
United States
Type: Equity
MD price evolution
MD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $19.4 | $8 | $73.26 | |
| Short term investments | $113.8 | $107.47 | $104.48 | |
| Net receivables | $288.1 | $274.16 | $283.75 | $272.31 |
| Inventory | ||||
| Total current assets | $528.22 | $429.21 | $426.52 | $483.45 |
| Long term investments | ||||
| Property, plant & equipment | $98.49 | $113.28 | $144.62 | $145.93 |
| Goodwill & intangible assets | $1249.2 | $1412.01 | $1405.41 | |
| Total noncurrent assets | $1566.14 | $1741.64 | $1736.36 | |
| Total investments | $113.8 | $107.47 | $104.48 | |
| Total assets | $2076.87 | $1995.35 | $2168.16 | $2219.81 |
| Current liabilities | ||||
| Accounts payable | $47.37 | $267.33 | $207.03 | $350.8 |
| Deferred revenue | ||||
| Short long term debt | $36.49 | $37.44 | $35.99 | |
| Total current liabilities | $373.08 | $310.16 | $247.28 | $388.95 |
| Long term debt | $607.45 | $661.82 | $741.22 | $665.66 |
| Total noncurrent liabilities | $978.73 | $1064.69 | $981.8 | |
| Total debt | $698.31 | $778.66 | $701.65 | |
| Total liabilities | $1344.38 | $1288.89 | $1311.97 | $1370.75 |
| Shareholders' equity | ||||
| Retained earnings | -$279.02 | -$298.46 | -$145.44 | -$149.47 |
| Other shareholder equity | -$0.21 | -$1.95 | -$2.15 | -$2.21 |
| Total shareholder equity | $706.46 | $856.2 | $849.06 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $73.26 | $9.82 | $387.39 | $1123.84 |
| Short term investments | $104.48 | $93.24 | $99.72 | $104.87 |
| Net receivables | $272.31 | $296.79 | $301.77 | $241.93 |
| Inventory | ||||
| Total current assets | $483.45 | $427.99 | $840.56 | $1549.35 |
| Long term investments | ||||
| Property, plant & equipment | $145.93 | $140.21 | $135.62 | $132.16 |
| Goodwill & intangible assets | $1405.41 | $1550.58 | $1526.99 | $1504.61 |
| Total noncurrent assets | $1736.36 | $1919.9 | $1881.98 | $1798.6 |
| Total investments | $104.48 | $93.24 | $99.72 | $104.87 |
| Total assets | $2219.81 | $2347.89 | $2722.55 | $3347.95 |
| Current liabilities | ||||
| Accounts payable | $350.8 | $31.86 | $394.12 | $423.16 |
| Deferred revenue | ||||
| Short long term debt | $35.99 | $36.49 | $22.17 | $21.15 |
| Total current liabilities | $388.95 | $426.98 | $427.37 | $444.33 |
| Long term debt | $665.66 | $636.38 | $1043.65 | $1783.56 |
| Total noncurrent liabilities | $981.8 | $1029.27 | $1398.49 | $2155.9 |
| Total debt | $701.65 | $717.08 | $1065.83 | $1804.71 |
| Total liabilities | $1370.75 | $1456.26 | $1825.85 | $2600.23 |
| Shareholders' equity | ||||
| Retained earnings | -$149.47 | -$89.06 | -$155.39 | -$286.35 |
| Other shareholder equity | -$2.21 | -$3.73 | $1.32 | $3.53 |
| Total shareholder equity | $849.06 | $891.63 | $896.49 | $747.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $511.16 | $504.3 | $495.1 | $496.44 |
| Cost of revenue | $390.18 | $400.22 | $395.28 | |
| Gross Profit | $114.12 | $94.88 | $101.17 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $56.56 | $60.2 | $53.06 | |
| Total operating expenses | $458.71 | $260.97 | $78.99 | $212.66 |
| Operating income | -$146.85 | $15.89 | -$111.49 | |
| Income from continuing operations | ||||
| EBIT | -$157.42 | $18.42 | -$128.77 | |
| Income tax expense | $5.79 | -$14.7 | $3.79 | -$14.56 |
| Interest expense | -$8.59 | $10.31 | $10.6 | $10.08 |
| Net income | ||||
| Net income | $19.44 | -$153.03 | $4.04 | -$124.29 |
| Income (for common shares) | -$153.03 | $4.04 | -$124.29 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1994.64 | $1972.02 | $1911.19 | $1733.95 |
| Cost of revenue | $1573.08 | $1504.99 | $1397.95 | $1284.63 |
| Gross Profit | $421.56 | $467.03 | $513.24 | $449.32 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $227.54 | $231.4 | $263.36 | $248.95 |
| Total operating expenses | $414.24 | $294.35 | $310.32 | $351.19 |
| Operating income | $7.32 | $172.69 | $202.92 | $98.13 |
| Income from continuing operations | ||||
| EBIT | -$6.28 | $124.84 | $226.93 | -$669.28 |
| Income tax expense | $12.05 | $18.81 | $27.24 | $16.73 |
| Interest expense | $42.08 | $39.7 | $68.72 | $110.48 |
| Net income | ||||
| Net income | -$60.41 | $66.33 | $130.96 | -$796.49 |
| Income (for common shares) | -$60.41 | $66.33 | $130.96 | -$796.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$153.03 | $4.04 | -$124.29 | |
| Operating activities | ||||
| Depreciation | $8.79 | $10.31 | $9.06 | |
| Business acquisitions & disposals | -$8.17 | -$5 | ||
| Stock-based compensation | $1.95 | $3.07 | $3.02 | |
| Total cash flows from operations | $106.95 | -$125.23 | $69.25 | |
| Investing activities | ||||
| Capital expenditures | -$6.96 | -$5.33 | -$9.04 | |
| Investments | -$5.93 | -$2.74 | $0.93 | |
| Total cash flows from investing | -$33.47 | -$12.89 | -$16.24 | -$12.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.14 | -$0.03 | $1.04 | |
| Net borrowings | -$83.83 | $76.19 | -$3.64 | |
| Total cash flows from financing | -$9.52 | -$82.66 | $76.2 | -$4.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $30.57 | $11.4 | -$65.26 | $52.08 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$60.41 | $66.33 | $130.96 | -$796.49 |
| Operating activities | ||||
| Depreciation | $36.17 | $35.64 | $32.15 | $28.44 |
| Business acquisitions & disposals | -$6.67 | -$28.17 | -$29.93 | -$1.15 |
| Stock-based compensation | $12.32 | $16.13 | $18.97 | $39.04 |
| Total cash flows from operations | $137.32 | $166.94 | $76.74 | $204.62 |
| Investing activities | ||||
| Capital expenditures | -$33.33 | -$29.71 | -$7.52 | -$28.79 |
| Investments | -$8.99 | -$0.46 | -$18.56 | -$28.41 |
| Total cash flows from investing | -$48.18 | -$56.95 | -$53.07 | $815.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.99 | -$83.11 | $2.13 | -$1.48 |
| Net borrowings | -$19.12 | -$413.79 | -$762.66 | -$1.67 |
| Total cash flows from financing | -$25.71 | -$487.55 | -$760.12 | -$4.16 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $63.43 | -$377.57 | -$736.45 | $1015.97 |
News
|
Long-Term Returns of Paul Singer’s Activist Targets
Insider Monkey via Yahoo Finance
16 Sep 2023
|
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance
31 Mar 2023
|
|
7 Cheap Stocks That Could Increase 10X by 2027
InvestorPlace via Yahoo Finance
31 Aug 2022
|
|
Mednax (MD) Q2 Earnings Match Estimates
Zacks via Yahoo Finance
4 Aug 2022
|
|
Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth
Zacks via Yahoo Finance
16 Jul 2022
|
|
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap...
Zacks via Yahoo Finance
11 Jul 2022
|
|
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
Zacks via Yahoo Finance
23 Jun 2022
|
|
7 Cheap Stocks Under $20 That Could Double Soon
InvestorPlace via Yahoo Finance
7 Jun 2022
|
|
Does The Market Have A Low Tolerance For MEDNAX, Inc.'s (NYSE:MD) Mixed Fundamentals?
Simply Wall St. via Yahoo Finance
4 May 2022
|
|
74 Biggest Movers From Yesterday
Benzinga
29 Apr 2022
|
Fundamentals
| Market cap | $1.27B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 85.87M |
| Revenue | $2.01B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$253.84M |
| Revenue Q/Q | 0.90% |
| Revenue Y/Y | -0.25% |
| P/E ratio | -4.99 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.63 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.96 |
|---|---|
| ROA | -12.00% |
| ROE | N/A |
| Debt/Equity | 1.61 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.42 |
| Quick ratio | N/A |